American Society of Clinical Oncology

SHERPA: White

People

  1. Morris
    Morris
  2. Scher
    Scher
  3. Brennan
    Brennan
  4. Coit
    Coit
  5. Gonen
    Gonen
  6. Jarnagin
    Jarnagin
  7. Fox
    Fox
  8. Schoder
    Schoder
  9. D'Angelica
    D'Angelica
  10. Danila
    Danila

Groups

  1. Molecular Pharmacology and Chemistry Program Faculty (22)
  2. Sloan Kettering Institute Faculty (22)
  3. Department of Medicine (16)
  4. GSK Faculty (13)
  5. Solid Tumor Oncology Division (13)
  6. Epidemiology and Biostatistics (11)
  7. Surgery (11)
  8. Molecular Imaging and Therapy Service (10)
  9. Radiology, Department of (10)
  10. Biostatistics Service (8)
Search Within
  1. "2011"
  2. "Molecular Pharmacology and Chemistry Program Faculty"
Formats
  1. Meeting Abstract (22)
Groups
  1. Molecular Pharmacology and Chemistry Program Faculty (22)
  2. Sloan Kettering Institute Faculty (22)
  3. Department of Medicine (16)
  4. GSK Faculty (13)
  5. Solid Tumor Oncology Division (13)
  6. Epidemiology and Biostatistics (11)

More Groups

People
  1. Steven Larson (10)
  2. Howard Scher (8)
  3. Michael Morris (8)
  4. Murray Brennan (7)
  5. Daniel Coit (4)
  6. Mithat Gonen (4)

More People

Years
  1. 2011 (22)
Publications
  1. Journal of Clinical Oncology (22)

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluation of putative prognostic tissue biomarkers in pancreatic ductal adenocarcinoma
    Meeting Abstract

    Winter, J. M.; Tang, L. H.; Klimstra, D. S.; Brennan, M. F.; O'Reilly, E. M.; Jarnagin, W. R.; Allen, P. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Borwick, L. S.; Momen, L.; Curley, T.; Arauz, G.; Larson, S. M.; Fleisher, M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Slovin, S. F.; Morris, M. J.; Steinbrecher, J. E.; Chen, Y.; Fleisher, M.; Larson, S. M.; Sawyers, C. L.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Phase II single-arm, single-institution trial of neoadjuvant gemcitabine and oxaliplatin treatment (NT) in patients (pts) with resectable pancreas adenocarcinoma (PC)
    Meeting Abstract

    O'Reilly, E. M.; Jarnagin, W. R.; Brennan, M. F.; Winston, C.; Tang, L. H.; Capanu, M.; Schattner, M.; Chen, L. Y.; DeMatteo, R. P.; DiMaio, C. J.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Standardized uptake value (SUV) by positron emission tomography/computed tomography (PET/CT) as a prognostic variable in metastatic breast cancer (MBC)
    Meeting Abstract

    Morris, P. G.; Fazio, M.; Jhaveri, K. L.; Serna-Tamayo, C.; Eaton, A.; Patil, S.; Ulaner, G.; Howard, J.; Larson, S. M.; Hudis, C.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Toward a rational strategy for prostate cancer screening based on long-term risk of prostate cancer metastases and death: Data from a large, unscreened, population-based cohort followed for up to 30 years
    Meeting Abstract

    Lilja, H.; Savage, C.; Gerdtsson, A.; Bjork, T.; Manjer, J.; Nilsson, P.; Dahlin, A.; Bjartell, A.; Scardino, P. T.; Ulmert, D.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM)
    Meeting Abstract

    Krug, L. M.; Tsao, A. S.; Kass, S.; Rusch, V. W.; Travis, W. D.; Panageas, K.; Adusumili, P. S.; Kris, M. G.; Maslak, P. G.; Scheinberg, D. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Initial study of bone scan tumor area for early surrogate outcome assessment in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Kim, H. J.; Brown, M. S.; Chu, G. H.; Gjertson, D. W.; Auerbach, M.; Poon, C.; Vidovic, A.; Ramakrishna, B.; Morris, M. J.; Larson, S. M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Phase I trial of the targeted alpha-particle nano-generator actinium-225 ((225)Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML)
    Meeting Abstract

    Jurcic, J. G.; Rosenblat, T. L.; McDevitt, M. R.; Pandit-Taskar, N.; Carrasquillo, J. A.; Chanel, S. M.; Ryan, C.; Frattini, M. G.; Cicic, D.; Larson, S. M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer
    Meeting Abstract

    Gajria, D.; King, T. A.; Pannu, H.; Sakr, R.; Seidman, A. D.; Syldor, A.; Patil, S.; Maybody, M.; Norton, L.; Rosen, N.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save